

Esophageal Oncology group : Treatment map July.2026.

UICC 8th	Standard treatment in Japan		Trials ongoing or follow up	
Stage I (N0)	Endoscopic resection (ESD/EMR) + CRT		JCOG1904 CRT: IFI⁵⁾ vs. ENI⁶⁾ 2020/03~ Follow up period	
Stage I (N1)	Esophagectomy (Thoracoscopic or open esophagectomy) ¹⁾	Concurrent CRT (CF-RT ⁴⁾)	JCOG2013 (±NeoCF²⁾/DCF³⁾ Esophagectomy: Upper and Middle thoracic Esophageal Squamous Cell Cancer SCLN⁸⁾ Dissection vs Preservation 2022/8~ Ongoing	
Stage II	Neoadjuvant chemotherapy (Neo DCF ³⁾) + Esophagectomy (Thoracoscopic or open esophagectomy) ¹⁾	Adjuvant Nivolumab (After CRT + Esophagectomy)	JCOG2206 NeoCF²⁾/DCF³⁾ + Esophagectomy: Surgery alone vs Nivolumab vs S-1 2023/7~ Ongoing	
Stage III	Neoadjuvant chemotherapy + Esophagectomy ¹⁾	Concurrent CRT (CF-RT ⁴⁾ or Surataadenoturev-RT)	JCOG2203 Adenocarcinoma of EGJ⁹⁾ Esophagectomy: Upfront surgery vs Neo DOS¹⁰⁾/FLOT⁷⁾ 2023/7~ Ongoing	
T4a/M1LYM* Resectable	Neoadjuvant chemotherapy + Esophagectomy ¹⁾	Concurrent CRT	JCOG1510 Concurrent CRT vs. Induction DCF³⁾ + Concurrent CRT or Esophagectomy 2018/2~ 2023.8→ Follow up period	
T4b/M1LYM* Unresectable	Concurrent CRT			
Stage IVB	1 st line therapy: CF ²⁾ + Pembrolizumab CF ²⁾ + Nivolumab CF ²⁾ + Tislelizumab	2 nd or later line therapy: Paclitaxel Docetaxel Nivolumab, Tislelizumab, Pembrolizumab (CPS ≥10) T-DXd (HER2 positive) ¹¹⁾	JCOG2311 Radiation therapy + Nivolumab + Ipilimumab vs. Nivolumab + Ipilimumab 2014/11~ Ongoing	
Recurrent				

*M1LYM due to supraclavicular lymph node only 1) 2-3 field lymph node dissection 2) CF, CDDP + 5-FU 3) DCF, DOC + CDDP + 5-FU 4) CF-RT, CDDP + 5-FU + radiation
 5) IFI, Involved field irradiation 6) ENI, Elective lymph node irradiation 7) FLOT, 5-FU + LV + L-OHP + DOC 8) SCLN, Supraclavicular lymph node
 9) EGJ, Esophagogastric junction 10) DOS, DOC + L-OHP + S-1 11) T-DXd, Trastuzumab deruxtecan